Is QNRX or JUNS more profitable?

Jupiter Neurosciences' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.57% -221.17% Jupiter Neurosciences N/A N/A -246.66%

Does the media favor QNRX or JUNS?

In the previous week, Jupiter Neurosciences had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 3 mentions for Quoin Pharmaceuticals. Jupiter Neurosciences' average media sentiment score of 0.49 beat Quoin Pharmaceuticals' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend TRAW or JUNS?

Traws Pharma currently has a consensus price target of $1.00, indicating a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Traws Pharma is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TRAW or JUNS more profitable?

Jupiter Neurosciences' return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Traws Pharma N/A -23,868.92% -165.52% Jupiter Neurosciences N/A N/A -246.66%

Does the media favor TRAW or JUNS?

In the previous week, Jupiter Neurosciences had 4 more articles in the media than Traws Pharma. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 2 mentions for Traws Pharma. Jupiter Neurosciences' average media sentiment score of 0.49 beat Traws Pharma's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jupiter Neurosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate OBSV or JUNS?

Given ObsEva's higher probable upside, research analysts plainly believe ObsEva is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is OBSV or JUNS more profitable?

Jupiter Neurosciences' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Jupiter Neurosciences N/A N/A -246.66%

Do analysts rate JUNS or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer JUNS or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is JUNS or CURX more profitable?

Jupiter Neurosciences' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A N/A -246.66% Curanex Pharmaceuticals N/A -82.07% -79.65%

Jupiter Neurosciences (JUNS) Competitors

$2.85 +0.08 (+2.89%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$2.87 +0.02 (+0.67%)

As of 10/9/2026 07:30 PM Eastern

Compare

JUNS vs. QNRX, TRAW, OBSV, ENSC, and CURX

Should you buy Jupiter Neurosciences stock or one of its competitors? Jupiter Neurosciences's main competitors and comparable companies include Quoin Pharmaceuticals (QNRX), Traws Pharma (TRAW), ObsEva (OBSV), Ensysce Biosciences (ENSC), and Curanex Pharmaceuticals (CURX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Jupiter Neurosciences compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Quoin Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 11.2% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Jupiter Neurosciences' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.57%	-221.17%
Jupiter Neurosciences	N/A	N/A	-246.66%

Jupiter Neurosciences has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$25.18	N/A
Jupiter Neurosciences	$20K	129.68	-$8.65M	-$19.12	N/A

Quoin Pharmaceuticals presently has a consensus target price of $20.00, suggesting a potential upside of 344.44%. Given Quoin Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Quoin Pharmaceuticals is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 3 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 3 mentions for Quoin Pharmaceuticals. Jupiter Neurosciences' average media sentiment score of 0.49 beat Quoin Pharmaceuticals' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Jupiter Neurosciences beats Quoin Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

8.0% of Traws Pharma shares are held by institutional investors. 7.6% of Traws Pharma shares are held by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Jupiter Neurosciences had 4 more articles in the media than Traws Pharma. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 2 mentions for Traws Pharma. Jupiter Neurosciences' average media sentiment score of 0.49 beat Traws Pharma's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Traws Pharma has higher revenue and earnings than Jupiter Neurosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A
Jupiter Neurosciences	$20K	129.68	-$8.65M	-$19.12	N/A

Traws Pharma currently has a consensus price target of $1.00, indicating a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe Traws Pharma is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	-23,868.92%	-165.52%
Jupiter Neurosciences	N/A	N/A	-246.66%

Traws Pharma has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

Summary

Traws Pharma and Jupiter Neurosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Jupiter Neurosciences compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

17.5% of ObsEva shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Given ObsEva's higher probable upside, research analysts plainly believe ObsEva is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has higher revenue and earnings than ObsEva. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Jupiter Neurosciences	$20K	129.68	-$8.65M	-$19.12	N/A

Jupiter Neurosciences' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Jupiter Neurosciences	N/A	N/A	-246.66%

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

In the previous week, Jupiter Neurosciences had 6 more articles in the media than ObsEva. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 0 mentions for ObsEva. Jupiter Neurosciences' average media sentiment score of 0.49 beat ObsEva's score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ObsEva	Neutral
Jupiter Neurosciences	Neutral

Summary

Jupiter Neurosciences beats ObsEva on 8 of the 13 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Ensysce Biosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

5.6% of Ensysce Biosciences shares are held by institutional investors. 38.6% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Jupiter Neurosciences has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Jupiter Neurosciences' return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	N/A	-246.66%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Jupiter Neurosciences has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has higher revenue and earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	129.68	-$8.65M	-$19.12	N/A
Ensysce Biosciences	N/A	N/A	-$10.18M	-$2.76	N/A

In the previous week, Jupiter Neurosciences had 5 more articles in the media than Ensysce Biosciences. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 1 mentions for Ensysce Biosciences. Jupiter Neurosciences' average media sentiment score of 0.49 beat Ensysce Biosciences' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Neutral
Ensysce Biosciences	Neutral

Summary

Jupiter Neurosciences beats Ensysce Biosciences on 10 of the 12 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Curanex Pharmaceuticals?

Jupiter Neurosciences (NASDAQ:JUNS) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Jupiter Neurosciences has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, suggesting that its stock price is 388% less volatile than the broader market.

Jupiter Neurosciences' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	N/A	-246.66%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Curanex Pharmaceuticals has lower revenue, but higher earnings than Jupiter Neurosciences. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	129.68	-$8.65M	-$19.12	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Jupiter Neurosciences had 5 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 6 mentions for Jupiter Neurosciences and 1 mentions for Curanex Pharmaceuticals. Jupiter Neurosciences' average media sentiment score of 0.49 beat Curanex Pharmaceuticals' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Neutral
Curanex Pharmaceuticals	Neutral

Summary

Jupiter Neurosciences beats Curanex Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60M	$12.42B	$7.26B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	N/A	636.89	201.60	20.20
Price / Sales	129.68	746.40	581.89	87.91
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	-0.71	10.71	11.22	6.33
Net Income	-$8.65M	$2.84B	$3.50B	$382.15M
7 Day Performance	11.76%	-0.94%	-0.89%	-1.40%
1 Month Performance	-9.52%	-4.89%	-4.42%	-3.47%
1 Year Performance	-97.64%	-4.12%	7.03%	1.18%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JUNS Jupiter Neurosciences	0.4756 of 5 stars	$2.85 +2.9%	N/A	-97.6%	$2.60M	$20K	N/A	5	Gap Up
QNRX Quoin Pharmaceuticals	4.1697 of 5 stars	$4.63 -1.8%	$20.00 +331.6%	-44.9%	$9.31M	N/A	N/A	6	Short Interest Decrease Gap Down
TRAW Traws Pharma	2.0104 of 5 stars	$0.57 +4.2%	$1.00 +76.1%	-85.8%	$8.68M	$2.79M	N/A	7
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50	Gap Up
ENSC Ensysce Biosciences	1.6391 of 5 stars	$0.40 +1.1%	N/A	-77.4%	$7.86M	$5.07M	N/A	10	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. QNRX, TRAW, OBSV, ENSC, and CURX

How does Jupiter Neurosciences compare to Quoin Pharmaceuticals?

Summary

How does Jupiter Neurosciences compare to Traws Pharma?

Summary

How does Jupiter Neurosciences compare to ObsEva?

Summary

How does Jupiter Neurosciences compare to Ensysce Biosciences?

Summary

How does Jupiter Neurosciences compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. QNRX, TRAW, OBSV, ENSC, and CURX

How does Jupiter Neurosciences compare to Quoin Pharmaceuticals?

Which has more risk & volatility, QNRX or JUNS?

Do insiders and institutionals hold more shares of QNRX or JUNS?

Is QNRX or JUNS more profitable?

Which has better earnings and valuation, QNRX or JUNS?

Do analysts prefer QNRX or JUNS?

Does the media favor QNRX or JUNS?

Summary

How does Jupiter Neurosciences compare to Traws Pharma?

Do insiders and institutionals believe in TRAW or JUNS?

Does the media favor TRAW or JUNS?

Which has preferable earnings & valuation, TRAW or JUNS?

Do analysts recommend TRAW or JUNS?

Is TRAW or JUNS more profitable?

Which has more volatility & risk, TRAW or JUNS?

Summary

How does Jupiter Neurosciences compare to ObsEva?

Do insiders & institutionals believe in OBSV or JUNS?

Do analysts rate OBSV or JUNS?

Which has preferable valuation and earnings, OBSV or JUNS?

Is OBSV or JUNS more profitable?

Which has more volatility & risk, OBSV or JUNS?

Does the media prefer OBSV or JUNS?

Summary

How does Jupiter Neurosciences compare to Ensysce Biosciences?

Do insiders and institutionals hold more shares of JUNS or ENSC?

Is JUNS or ENSC more profitable?

Which has more risk and volatility, JUNS or ENSC?

Do analysts rate JUNS or ENSC?

Which has higher valuation and earnings, JUNS or ENSC?

Does the media refer more to JUNS or ENSC?

Summary

How does Jupiter Neurosciences compare to Curanex Pharmaceuticals?

Which has more risk & volatility, JUNS or CURX?

Is JUNS or CURX more profitable?

Which has better valuation & earnings, JUNS or CURX?

Do analysts prefer JUNS or CURX?

Does the media prefer JUNS or CURX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools